Liquid biopsy offers a breakthrough solution for the early detection and dynamic monitoring of cancer. It provides reliable, targeted information without any invasive procedure.

One of the greatest challenges in cancer diagnostics today is obtaining a real-time, accurate picture of the biological processes occurring in the body. These biological changes begin long before they become physically visible.
Traditional tissue biopsy is an invasive, painful procedure, and in many cases it provides information only from one region of the tumor. As a result, it may fail to reflect the full genetic diversity of the tumor.
Moreover, a biopsy offers only a single snapshot in time and cannot be repeated indefinitely. Imaging tests are also essential, but they are expensive and often detect abnormalities only once the tumor has reached a certain size and has already caused structural changes in the tissue.
“The time gained through early detection can significantly influence treatment decisions and improve survival outcomes.”
This method is a modern diagnostic technology based on the analysis of free nucleic acids and tumor-derived DNA and RNA fragments extracted from various body fluids (such as saliva, blood, or urine).
Tumors release tiny genetic signals into the circulation even in very early stages. The more active the tumor’s growth, the more of these molecular signals appear. Changes in their quantity and genetic patterns can be monitored in real time.
Because liquid biopsy analyzes tumor-derived genetic signals present in the circulation and in excreted body fluids, it is able to reflect the different biological behaviors of various regions of the tumor.
If a treatment is effective, the amount of tumor-derived nucleic acids may decreas over time. With this method, the entire course of the disease can be continuously monitored.
In the case of prostate cancer, detecting the TMPRSS2–ERG gene fusion is particularly important. This fusion is present in about half of prostate tumors in the European population, and due to its high specificity, it is one of the most reliable biomarkers.
The TMPRSS2–ERG gene fusion is a genetic rearrangement in which the androgen-sensitive TMPRSS2 gene abnormally connects with the ERG oncogene.
Under normal circumstances, these genes function independently of each other. The fusion, however, alters gene regulation: the hormone-sensitive TMPRSS2 gene 'turns on' the ERG gene. As a result, the production of the ERG protein increases abnormally, triggering molecular processes that promote cell proliferation and tumor formation.
The genes function independently.
The hormone‑sensitive TMPRSS2 gene activates the ERG oncogene.
Overproduction of ERG protein Cell proliferation Tumor formation
This biomarker is the foundation of PC‑Alarm Focus
PC-Alarm Focus is designed to detect this biomarker using liquid biopsy technology from a urine sample, applying a high-sensitivity real-time reverse transcription polymerase chain reaction (qRT-PCR) analysis.
While PSA levels are often uncertain and potentially misleading, the presence of the TMPRSS2–ERG fusion provides far more accurate and reliable information for the physician.
